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Introduction 
 Prenatal diagnosis still depends on 
invasive methods using cells contained in the 
amniotic fluid or villus cells (Suzumori, 
1999).  These procedures carry a small but 
important rate of miscarriage (Vyas, 1994).  
The discovery on the presence of foetal cells 
in maternal circulation was a turning point for 
the development of a safe, accurate and 
reliable prenatal diagnosis, which could be 
offered to as a routine test to any pregnant 
women regardless their age. 
 Genetic analysis of the identified foetal 
cells or foetal DNA has relied primarily on 
fluorescence in situ hybridisation (FISH) and 
polymerase chain reaction (PCR) to amplify 
unique foetal gene sequences (Goldberg, 
1997).  PCR is known to be a powerful tool in 
amplifying small amounts of DNA thus, it is 
very useful in detecting genetic diseases from 
foetal DNA isolated from maternal blood.   
 In this study, the ability to detect foetal 
DNA and foetal cells in a minimal amount of 
maternal blood taken during the first, second 
and third trimester of pregnancy was first 
investigated.  The presence of foetal DNA in 
the maternal blood taken from the forearm and 
fingertip was detected using PCR.  Foetal 
haemoglobin (HbF) staining was also 
performed using maternal blood smears in 
order to isolate the foetal cells and subjected it 
to PCR for confirmation.  Next, the 
development of a new assay using real-time 
quantitative PCR was attempted.  The SOD-1 
gene, which is at the Down Syndrome Critical 
Region was chosen for the reason that the 
triplication of the genes in that region could 
give the effect seen in Down syndrome.  As 
this approach is focused on the gene involved 
in the disorder, it can be used for all 
pregnancies regardless of the sex of the foetus. 
 
Materials and Methods 
 
Study subjects 
Pregnant women attending the antenatal 
clinic of Department of Obstetrics and 
Gynaecology at the Hospital Kuala Lumpur 
were recruited.  Blood samples (200 µl) from 
the tip of the finger were taken using a lancing 
device (Roche Diagnostic, Germany) and 
were collected in sterile microcentrifuge 
tubes.  For foetal haemoglobin staining and 
real-time quantitative analysis the blood 
samples were drawn from the forearm and 
were collected in lithium-heparinised tubes.  
In addition, a male blood sample was also 
obtained to be used as control.  For non-
invasive prenatal DNA screening test of Down 
syndrome, the blood samples of two pregnant 
women carrying Down syndrome foetus were 
obtained from the Fetal Medicine and Health 
Clinic, Cheras.  The mean gestational age of 
the subjects carrying euploid normal foetuses 
at first, second and third trimesters were 9.2, 
18.7 and 32.1 weeks, respectively.  The mean 
gestational age of the subjects carrying normal 
twin foetuses and Down syndrome foetuses 
were 23.5 and 19.5 weeks, respectively.  
Down syndrome patients from Wisma 
Harapan, Kuala Lumpur, a school for the 
mentally challenged children and normal 
individuals were recruited for this study as 
controls.  Informed consent was obtained in 
each instance, as was ethical approval by the 
Faculty of Medicine and Health Sciences, 
Universiti Putra Malaysia, ethics committee.   
 
Genomic DNA extraction 
DNA extraction and purification were 
performed from 200 µl of whole blood using 
QIAamp DNA Mini Kit (Qiagen, Germany) 
according to the “blood and body fluid spin 
protocol” as recommended by the 
manufacturer.  The DNA preparations were 
eluted in 100 µl of nuclease free water 
(Eppendorf, Germany) 
 
Foetal haemoglobin staining 
Ten maternal blood samples of the first, 
second and third trimester male pregnancies 
were used for foetal haemoglobin staining. 
One microliter of the fresh maternal blood, 
which was collected in the lithium-heparinised 
tubes (Meus, Italy), was used to make a thin 
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blood film on a clean glass slide (Corning, 
Canada).  Foetal cells were identified using a 
foetal cell stain kit (Sigma, USA) according to 
the manufacturer’s instructions. 
 
Microscopy and cell scraping 
The stained slides were examined using a 
light microscope (Olympus, CHK2-F-GS, 
Japan) with x100, x400 and x1000 
magnifications.  The positively stained foetal 
nucleated cells were identified and counted.  
These cells were individually scraped with a 
sterile needle.  Approximately 8-10 cells were 
transferred to a 0.5 ml eppendorf tube 
containing 5 µl sterile distilled free water.  
 
PCR of foetal DNA 
All reactions were set up in a PCR 
workstation with precautions to avoid 
contaminations.  DNA from a male and a non-
pregnant female were used as controls.  A 
negative control without template was also 
performed to ensure no contamination took 
place during the experiment.  PCR 
amplification of venous blood drawn from the 
forearm was performed in a total volume of 20 
µl containing 100 ng genomic DNA, 200 µM 
dNTPs, 5 pmole of SRY-109F and SRY-245R 
primers (Lo et al., 1998) (Genbank sequence 
accession number: L08063), 1.5 mM MgCl2, 
1X Taq Polymerase buffer and 2.5 U Taq 
Polymerase (Promega, USA).  Thermal 
cycling was initiated with 10 minutes at 95ºC, 
followed by 40 cycles of 95ºC for 15 seconds, 
58ºC for 1 minute and 72ºC for 1 minute, then 
a final extension step of 72ºC for 10 minutes 
using a PCR machine (Eppendorf, 
Mastercycler Gradient, Germany).   
 
PCR of foetal cells 
The scraped foetal cells in 5 µl sterile 
distilled water were subjected to the PCR 
conditions described above (as for venous 
blood) but with the addition of 30 cycles of 
the denaturing, annealing and extension steps. 
 
Electrophoresis 
The PCR products (5 µl) were analysed by 
electrophoresis in a 1.5% ethidium bromide 
(Bio-Rad, USA) stained agarose (Amresco, 
USA) gel.  The gel was photographed using a 
documentation and analysis system (Eastman 
Kodak Company, USA). 
 
TaqMan real-time quantitative PCR 
 In essence, SOD-1 gene sequence was 
used as a molecular marker to detect Down 
syndrome pregnancies.  Real-time quantitative 
PCR analysis was performed using the Rotor-
Gene 2000 (Corbett Research, Australia), 
which is essentially a combined thermal cycler 
and a fluorescence detector with the ability to 
monitor the progress of individual PCR 
reactions.  The primers and dual labelled 
probes for the SOD-1 gene (GenBank 
Acession Nr. M13267) were designed with the 
aid of Primer 3 Software.  The size of the 
fragment analysed was 88 bp.  
Glyceraldehydes-3-phosphate dehydrogenase 
(GAPDH) (GenBank Acession Nr. J04038) 
gene was used to serve as a control that DNA 
was indeed present in the sample analysed and 
the polymerase chain reaction was functional.  
The length of the fragment analysed was 97 
bp.   The sequences for the primers and probes 
combination used are shown in TABLE 1. 
 For the TaqMan PCR analysis, the 
amplification reactions were set up in a 
reaction volume of 20 µl containing 100 ng of 
the extracted DNA, 300 nM of each 
amplification primer and 100 nM of the deal 
labelled TaqMan probe and the necessary 
components provided in the Taqman PCR 
Core reaction Kit (Perkin Elmer, Branchburg, 
New Jersey, USA).  This corresponded to 2 µl 
of 10x Buffer A, 4 mM MgCl2, 200 µM each 
dATP, dCTP and dGTP, 400 µM dUTP, 1.25 
U AmpliTaq Gold and 0.5 U AmpErase.  The 
uracil N-glycolase activity of latter, in 
combination with dUTP, was used to prevent 
contamination by carry-over of PCR products.  
 The DNA were analysed for these two 
markers in the same analytic run since the 
thermal profiles for both the SOD-1 and 
GAPDH TaqMan assay were identical.  
Thermal cycling was carried using a 2 minute 
incubation at 50ºC (to permit AmpErase 
activity), followed by an initial denaturation 
step at 95ºC for 10 minutes, which facilitates 
activation of the AmpliTaq Gold polymerase 
activity, followed by 55 cycles of 15 seconds 
at 95ºC and 1 minute at 56ºC.
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TABLE 1     Sequences of real-time quantitative PCR primers and probes. 
 
 
 The results were expressed as copy 
numbers, whereby the conversion factor of 6.6 
pg of DNA per cell was used.  The number of 
copies of SOD-1 DNA present in the sample 
was determined using a known concentration 
of SOD-1 genomic DNA calibration curve.  
Amplification data were analysed by the use 
of the software developed by Corbett 
Research.  The mean quantity of each 
triplicate was used for further calculation.  
The concentration, expressed in copies per 
microliter, was calculated using the following 
equation  (Lo et al., 1998). 
          
 
 
 
Where C = target concentration in sample 
(copies per microliter); Q = target quantity 
(copies) determined by sequence detector in 
PCR; VDNA = total volume of DNA obtained 
after extraction, typically 100 µl per Qiagen 
extraction; VPCR = volume of DNA solution 
used for PCR; and Vext = volume of sample 
extracted, typically 200 µl. 
 
Statistics 
 The Student t-test was performed using 
Microsoft Excel.   
 
Results 
 
PCR of foetal DNA 
FIGURE 1 shows the presence of foetal 
SRY gene in the maternal blood taken from the 
tip of the finger.  Lanes 2-6 show the presence 
of male foetal DNA at gestational age from 6-
10 weeks.  However, no bands were seen in 
female pregnancies from 6-10 weeks gestation 
(lanes 8-12).  The intensity of the band at 137 
bp increases as the gestational age increases.  
Confirmation of the sex of the foetus was 
obtained by ultrasound at 24th week of 
gestation and again at birth. 
 
 
 
 
 
 
 
 
FIGURE 1 Polymerase chain reaction 
amplification of SRY gene from maternal blood. 
Lane 1 = male positive control; 2-6 = DNA from 
pregnant women with male foetus at 6, 7, 8, 9, 10 
weeks gestation, respectively; M = 50 bp DNA 
marker; 8-12 = DNA from pregnant women with 
female foetus at 6-10 weeks gestation, 
respectively; 13 = non-template control. 
 
Foetal haemoglobin staining and PCR of 
foetal cell 
Foetal haemoglobin is resistant to acid 
elution, therefore when the blood smears were 
immersed in acid buffer, adult haemoglobin 
was eluted from the erythrocytes, whereas 
foetal haemoglobin remained intact.  When 
the blood smears were subsequently stained, 
erythrocytes having foetal haemoglobin take 
up stain, while those containing only adult 
haemoglobin appear as “ghosts” (FIGURE 2).  
The ratio of nucleated foetal to maternal cell 
was found to be about 5 in 106.  FIGURE 3 
shows the results of the Y-specific region 
amplified giving a 137 bp band from the 
stained foetal cells using the SRY primers. 
 
 
 
 
 
 
 
FIGURE 2 Foetal haemoglobin staining of 
maternal blood smear.  Arrow indicates the stained 
foetal cell while maternal cells appear as ‘ghost’ 
cells; (oil immersion, 1000x). 
 
 
 SOD-1 GAPDH 
Forward 5’ gtg gta gtc tcc tgc agg tct 3’ 5’ ccc cac aca cat gca ctt a 3’ 
Reverse 5’ gcc ttc gtc gcc ata act 3’ 5’ cta gtc cca ggg ctt tga tt 3’ 
Probe 5’ (FAM)  ttc cgt tgc agt cct cgg aac 
(TAMRA) 3’ 
5’ (JOE) caa gtt gcc tgt cct tcc tag ctc tt 
(TAMRA) 3’  
       VDNA             1 
    C = Q x  ______  x   ______ , 
                     VPCR                  Vext 
 1    2    3   4   5    6   M   8    9   10  11  12  13       
137 bp 
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FIGURE 3 Polymerase chain reaction 
amplification of Y specific region of foetal cells 
scraped from foetal haemoglobin stained slides.  
Lane M = 50 bp marker; 1-3 = foetal cells from 
women with male foetus at 38, 38, 39 weeks 
gestation, respectively; 4 = male positive control. 
 
TaqMan real-time quantitative PCR 
 The mean concentrations of the SOD-1 
sequences in the blood of the study subjects 
are shown in TABLE 2.  The concentrations 
are expressed in copies/µl.  As hypothesized, 
the level of SOD-1 sequences in the Down 
syndrome patients is significantly high when 
compared to normal individuals (p =  9.35 x 
10-07). 
Our data show that the number of SOD-1 
sequences in maternal blood is not 
significantly increased when the first (p = 
0.575) and second trimester (p = 0.056) 
pregnancies were compared with the non-
pregnant women, however the concentration is 
significantly elevated in the third trimester 
from the non-pregnant women (p = 9.23 x 10-
05).  We analysed the data between the three 
trimesters of the normal pregnancies and 
found that there is no significant increases of 
the SOD-1-specific DNA between the first 
and second trimesters (p = 0.147) but 
significantly elevated in the third trimester 
when compared with the second trimester (p = 
0.002). 
 The analysis of twin pregnancies showed 
that SOD-1-specific DNA level is increased 
significantly when compared with the third 
trimester normal pregnancy (p = 0.003).  
Significantly more SOD-1 sequences were 
detected in blood samples from mothers 
carrying Down syndrome foetuses, compared 
with mothers carrying normal foetus in all 
three trimesters (p<0.05) and twin foetuses (p 
= 0.026). 
 
Discussion 
 Currently, invasive prenatal diagnostic 
procedures such as chorionic villus sampling 
and amniocentesis are usually offered to 
women 35 years of age and older, in the 
absence of specific foetal abnormalities, 
positive family history, or other indications of 
elevated risk (Bianchi et al., 1997).  A 
technique which is suitable to be applied to 
women at all age for non-invasive prenatal 
diagnosis by means of foetal cells and DNA in 
maternal blood is being developed at present.  
The current technology using this approach is 
focused on detecting Y-chromosomal 
sequences, which is impossible to be used for 
pregnancies involving female foetuses.  
Therefore, this study was carried out to 
investigate the presence of foetal cells and 
DNA in maternal blood and finally to make 
use of this source of foetal genetic material for 
prenatal screening of Down syndrome for 
women at all age regardless of the sex of the 
foetus.  
An experiment was conducted using 200 
microliters of maternal blood obtained from 
the tip of the finger at 6-10 weeks of gestation 
to detect the presence of foetal DNA.  This is 
the first ever report showing the ability to 
detect foetal DNA as early as 6 weeks of 
gestation in maternal blood obtained from the 
fingertip.  Many researchers (Biscoff et al., 
1998; Cheung et al., 1996 and Bianchi et al., 
1994) needed approximately 18 ml or more of 
maternal blood to carry out prenatal diagnosis 
or foetal cell detection.  These findings 
suggest that a small amount of maternal blood 
from the fingertip would be sufficient to 
perform prenatal diagnosis using maternal 
blood.  The foetal cell detection by HbF 
staining method showed increased foetal cells 
in the maternal blood in each trimester.  The 
ratio of nucleated foetal to maternal cells in 
non-enriched samples in this study was 2 in 
106 in the first trimester, 3 in 106 and 5 in 106 
in the second and third trimester of 
pregnancies, respectively.  Hamada and 
colleagues (1993) found that the concentration 
of foetal cells in non-enriched samples to be 
<1/100000 in the first trimester.  These 
findings suggest that a first trimester non-
invasive prenatal diagnosis approach might be 
feasible.   
 The TaqMan real-time quantitative PCR 
system has been used to determine the 
quantity of circulating foetal DNA in normal 
(Lo et al., 1998) and aneuploid pregnancies 
(Zhong et al., 2000) by analysis of the Y 
chromosomal sequences.  The main limitation 
of this quantitative analysis in maternal blood 
is that this approach can only be used in 
137 bp
500 bp 
200 bp 
100 bp 
M       1           2          3          4 
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TABLE 2     Quantitative analysis of SOD-1 sequence in blood using TaqMan Assay 
 
 
 
 
 
 
 
 
 
 
 
Values represent mean (range). 
a Significantly different from Non-pregnant women, p< 0.0001 
b Significantly different from third trimester, p<0.005  
c Significantly different from Down syndrome pregnancies, p<0.05 
 
pregnancies involving male foetuses.  For this 
reason, it is imperative that genes involved in 
a particular disorder be used in prenatal 
diagnosis or screening.  In this study, a 
successful analysis on the amount of SOD-1 
sequences (located on the Down Syndrome 
Critical Region, chromosome 21) in the 
maternal blood of pregnant women bearing 
normal and Down syndrome foetus and also in 
non-pregnant women and Down syndrome 
patients were made 
 Firstly, we looked at the levels of SOD-1 
sequences in the non-pregnant normal women 
and Down syndrome individuals.  The level is 
significantly elevated in the Down syndrome 
patients relative to the normal individuals.  
Next, we compared the concentrations of the 
 SOD-1-specific DNA between the non-
pregnant women and singleton pregnancy 
women at 3 different trimesters.  We found 
that the concentrations increased 1.6 and 3.3 
fold in the second and third trimester, 
respectively.  Comparison between the second 
and third trimester pregnancies also showed a 
2-fold increase of the sequence in the maternal 
blood.  These results suggest that the 
increment occurs due to the invasion of foetal 
cells into the maternal blood.  Our data 
correlate well with the observation by Lo and 
co-workers (Lo et al., 1998), which showed 
that the concentration of circulating foetal 
DNA constitutes 3% and 6% of the total 
circulating DNA in maternal plasma in the 
first and third trimesters and are generally low 
in the first trimester. 
 We also tested the level of the SOD-1 
sequence in twin pregnancies and finally 
analysed the concentration of the SOD-1-
specific DNA in pregnancies with Down 
syndrome.  Our results showed significant 
elevation of the sequence in the maternal 
blood when the Down pregnancies were 
compared with the normal singleton and twin 
pregnancies.  This indicated that more foetal 
cells invade the maternal circulation in the 
incidence of Down syndrome.  Our analysis 
balanced with the findings by Bianchi and co-
workers (1997) and Lo and colleagues (1999), 
in which they demonstrated that the number 
and concentration of circulating foetal 
cells/DNA increased in pregnancies involving 
foetuses affected by trisomy 21. 
Real-time PCR quantitation for prenatal 
screening could be performed by different 
laboratories, but it would probably be most 
practical to use a multiples of median (MoM) 
system akin to that which is currently used for 
the analysis of serum analytes (Zhong et al., 
2000). 
 Real-time quantitative PCR technology is 
an effective tool for prenatal diagnosis and 
screening which reduces the time and labour 
compared to the conventional cytogenetics 
method.  Even though our finding 
demonstrated that a gene involved in the 
particular disorder could be used in prenatal 
screening, a larger number of samples will be 
needed to determine the practicability of this 
method and to convert the screening test to 
diagnostic test. 
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